GSK Future Growth

How is GSK forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

2.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

LSE:GSK - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	32,876	6,461	6,930	8,821	12
12/31/2024	30,780	5,311	6,564	8,093	20
12/31/2023	28,923	4,881	5,235	7,191	21
9/30/2022	38,442	4,456	7,474	9,265	N/A
6/30/2022	37,240	4,574	7,927	10,506	N/A
3/31/2022	36,149	5,082	7,438	10,163	N/A
12/31/2021	34,114	4,385	5,793	7,952	N/A
9/30/2021	26,359	3,567	6,064	8,040	N/A
6/30/2021	28,378	3,934	4,871	6,339	N/A
3/31/2021	30,164	4,983	7,028	7,807	N/A
12/31/2020	34,099	5,749	7,457	8,441	N/A
9/30/2020	34,259	6,371	6,833	8,039	N/A
6/30/2020	34,998	6,679	8,751	9,693	N/A
3/31/2020	35,183	5,380	6,628	8,322	N/A
12/31/2019	33,754	4,645	6,261	8,020	N/A
9/30/2019	33,052	4,561	6,832	8,686	N/A
6/30/2019	31,759	4,427	6,488	8,248	N/A
3/31/2019	31,260	3,904	6,735	8,221	N/A
12/31/2018	30,821	3,623	6,881	8,421	N/A
9/30/2018	30,263	1,862	5,521	7,171	N/A
6/30/2018	30,014	1,656	5,140	6,991	N/A
3/31/2018	30,024	1,035	4,549	6,637	N/A
12/31/2017	30,186	1,532	4,764	6,918	N/A
9/30/2017	30,133	2,335	4,776	7,040	N/A
6/30/2017	29,832	1,931	4,865	6,910	N/A
3/31/2017	29,044	1,676	5,272	7,138	N/A
12/31/2016	27,889	912	4,428	6,497	N/A
9/30/2016	26,589	301	3,260	5,007	N/A
6/30/2016	25,174	31	N/A	3,721	N/A
3/31/2016	24,530	615	N/A	2,702	N/A

Earnings vs Savings Rate: GSK's forecast earnings growth (2.5% per year) is above the savings rate (1%).

Earnings vs Market: GSK's earnings (2.5% per year) are forecast to grow slower than the UK market (10.2% per year).

High Growth Earnings: GSK's earnings are forecast to grow, but not significantly.

Revenue vs Market: GSK's revenue (4.2% per year) is forecast to grow slower than the UK market (4.2% per year).

High Growth Revenue: GSK's revenue (4.2% per year) is forecast to grow slower than 20% per year.

Future ROE: GSK's Return on Equity is forecast to be high in 3 years time (31.6%)